Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens.


Journal

Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652

Informations de publication

Date de publication:
2019
Historique:
pubmed: 2 8 2019
medline: 19 2 2020
entrez: 2 8 2019
Statut: ppublish

Résumé

The devastating Ebola virus (EBOV) outbreak in West Africa in 2013-2016 has flagged the need for the timely development of vaccines for high-threat pathogens. To be better prepared for new epidemics, the WHO has compiled a list of priority pathogens that are likely to cause future outbreaks and for which R&D efforts are, therefore, paramount (R&D Blueprint: https://www.who.int/blueprint/priority-diseases/en/ ). To this end, the detailed characterization of vaccine platforms is needed. The vesicular stomatitis virus (VSV) has been established as a robust vaccine vector backbone for infectious diseases for well over a decade. The recent clinical trials testing the vaccine candidate VSV-EBOV against EBOV disease now have added a substantial amount of clinical data and suggest VSV to be an ideal vaccine vector candidate for outbreak pathogens. In this review, we discuss insights gained from the clinical VSV-EBOV vaccine trials as well as from animal studies investigating vaccine candidates for Blueprint pathogens.

Identifiants

pubmed: 31368826
doi: 10.1080/21645515.2019.1649532
pmc: PMC6816421
doi:

Substances chimiques

Ebola Vaccines 0
Vaccines, Attenuated 0
Viral Proteins 0
Viral Vaccines 0

Types de publication

Letter Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2269-2285

Références

Biotechnol Genet Eng Rev. 2018 Apr;34(1):122-138
pubmed: 29781359
PLoS One. 2009;4(5):e5547
pubmed: 19440245
Sci Rep. 2019 May 23;9(1):7755
pubmed: 31123310
J Infect Dis. 2011 Nov;204 Suppl 3:S1082-9
pubmed: 21987745
Vaccine. 2008 Dec 9;26(52):6894-900
pubmed: 18930776
PLoS One. 2014 Apr 23;9(4):e94355
pubmed: 24759889
Vaccine. 2019 Apr 10;37(16):2174-2178
pubmed: 30878249
J Infect Dis. 2011 Nov;204 Suppl 3:S1075-81
pubmed: 21987744
Virol Sin. 2019 Feb;34(1):106-110
pubmed: 30820837
Nature. 2015 Apr 30;520(7549):688-691
pubmed: 25853476
J Virol. 2011 Dec;85(23):12781-91
pubmed: 21917979
N Engl J Med. 2017 Oct 12;377(15):1438-1447
pubmed: 29020589
JAMA. 2015 Mar 24-31;313(12):1249-55
pubmed: 25742465
Vaccine. 2009 Feb 5;27(6):893-903
pubmed: 19070640
Science. 2015 Aug 14;349(6249):739-42
pubmed: 26249231
PLoS Pathog. 2007 Jan;3(1):e2
pubmed: 17238284
Lancet. 2017 Feb 4;389(10068):505-518
pubmed: 28017403
J Gen Virol. 2018 Jul;99(7):866-879
pubmed: 29869979
J Infect Dis. 2018 Nov 22;218(suppl_5):S582-S587
pubmed: 29939296
NPJ Vaccines. 2016;1:null
pubmed: 28706736
Emerg Infect Dis. 2015 Feb;21(2):305-7
pubmed: 25625358
Vaccine. 2015 Jun 4;33(24):2823-9
pubmed: 25865472
Viruses. 2014 Jan 31;6(2):516-23
pubmed: 24492621
Mem Inst Oswaldo Cruz. 2015 Jun;110(4):569-72
pubmed: 26061233
Vaccine. 2017 Aug 16;35(35 Pt A):4465-4469
pubmed: 28647166
J Virol. 2004 May;78(10):5458-65
pubmed: 15113924
Reprod Health. 2017 Dec 14;14(Suppl 3):157
pubmed: 29297408
Lancet. 2018 Mar 17;391(10125):1021
pubmed: 29565013
Nat Med. 2016 Jul 7;22(7):701-5
pubmed: 27387881
J Virol. 2011 Mar;85(5):2004-11
pubmed: 21177820
Lancet Infect Dis. 2018 Jul;18(7):738-748
pubmed: 29627147
Lancet Infect Dis. 2017 Dec;17(12):1276-1284
pubmed: 29033032
J Infect Dis. 2011 Nov;204 Suppl 3:S785-90
pubmed: 21987751
N Engl J Med. 2016 Apr 28;374(17):1647-60
pubmed: 25830326
Nat Commun. 2018 Aug 3;9(1):3067
pubmed: 30076287
Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1893-8
pubmed: 23319647
J Virol. 2009 Jul;83(14):7296-304
pubmed: 19386702
J Virol. 2017 Feb 28;91(6):
pubmed: 28077641
PLoS Med. 2017 Oct 6;14(10):e1002402
pubmed: 28985239
Genome Biol. 2017 Jan 19;18(1):4
pubmed: 28100256
J Infect Dis. 2019 Jan 29;219(4):556-561
pubmed: 30452666
Sci Transl Med. 2017 Apr 12;9(385):
pubmed: 28404856
EBioMedicine. 2017 May;19:107-118
pubmed: 28434944
Virus Genes. 2017 Aug;53(4):501-515
pubmed: 28447193
PLoS One. 2018 Sep 20;13(9):e0202753
pubmed: 30235286
MMWR Suppl. 2016 Jul 08;65(3):98-106
pubmed: 27387395
Vaccine. 2014 May 7;32(22):2637-44
pubmed: 24631094
Antiviral Res. 2014 Jan;101:26-9
pubmed: 24184127
Science. 2019 Jan 4;363(6422):74-77
pubmed: 30606844
J Virol. 2001 Sep;75(18):8724-32
pubmed: 11507217
J Virol. 2008 Jun;82(11):5664-8
pubmed: 18385248
NPJ Vaccines. 2019 Feb 8;4:8
pubmed: 30774999
Sci Rep. 2016 Jun 21;6:27944
pubmed: 27323685
J Virol. 2018 Jan 17;92(3):
pubmed: 29142131
Cell Rep. 2017 Aug 29;20(9):2251-2261
pubmed: 28854372
J Infect Dis. 2016 Mar 15;213(6):930-3
pubmed: 26563239
Int J Infect Dis. 2018 Sep;74:83-96
pubmed: 29981944
PLoS Negl Trop Dis. 2015 Apr 17;9(4):e0003736
pubmed: 25884628
Korean J Intern Med. 2018 Mar;33(2):233-246
pubmed: 29506344
PLoS Med. 2005 Jun;2(6):e183
pubmed: 15971954
J Virol. 1999 May;73(5):3723-32
pubmed: 10196265
Vaccine X. 2019 Jan 29;1:100009
pubmed: 31384731
Virology. 2008 Jun 20;376(1):165-72
pubmed: 18396306
Front Immunol. 2019 Jan 22;9:3071
pubmed: 30723475
Vaccine. 2018 Sep 25;:null
pubmed: 30266489
Antiviral Res. 2018 Feb;150:30-38
pubmed: 29246504
Hum Vaccin Immunother. 2017 Dec 2;13(12):2755-2762
pubmed: 28375764
CMAJ. 2017 Oct 30;189(43):E1326-E1327
pubmed: 29084758
J Infect Dis. 2017 Jun 15;215(12):1789-1798
pubmed: 28549145
Virology. 2005 Sep 30;340(2):174-82
pubmed: 16043204
MBio. 2019 May 28;10(3):
pubmed: 31138743
Vaccine. 2016 Jul 29;34(35):4196-4204
pubmed: 27373596
Arch Virol. 2010 Dec;155(12):2083-103
pubmed: 21046175
BioDrugs. 2019 Feb;33(1):9-14
pubmed: 30604389
Open Forum Infect Dis. 2015 Jun 05;2(3):ofv082
pubmed: 26199949
J Immunol. 2017 Apr 15;198(8):3023-3028
pubmed: 28289159
Lancet Infect Dis. 2017 Aug;17(8):854-866
pubmed: 28606591
Lancet. 2018 Mar 17;391(10125):1021-1022
pubmed: 29565012
Lancet. 2015 Aug 29;386(9996):857-66
pubmed: 26248676
Sci Rep. 2018 Jul 23;8(1):11043
pubmed: 30038228
J Virol. 2013 Jan;87(1):395-402
pubmed: 23077320
Lancet. 2006 Apr 29;367(9520):1399-404
pubmed: 16650649
J Virol. 2007 Feb;81(4):2056-64
pubmed: 17151112
N Engl J Med. 2018 Jun 21;378(25):2353-2355
pubmed: 29791249
Drug Des Devel Ther. 2018 Aug 14;12:2519-2527
pubmed: 30147299
CMAJ. 2017 Jun 19;189(24):E819-E827
pubmed: 28630358
Hum Vaccin Immunother. 2016 Sep;12(9):2327-33
pubmed: 27185081
J Virol. 2006 Oct;80(19):9659-66
pubmed: 16973570
Clin Infect Dis. 2016 Aug 1;63(3):376-9
pubmed: 27118786
NPJ Vaccines. 2019 Jan 25;4:5
pubmed: 30701094
Nat Microbiol. 2018 Oct;3(10):1084-1089
pubmed: 30150734
J Infect Dis. 2016 Oct 15;214(suppl 3):S360-S366
pubmed: 27496978
Lancet Infect Dis. 2015 Oct;15(10):1156-1166
pubmed: 26248510
J Infect Dis. 2007 Nov 15;196 Suppl 2:S404-12
pubmed: 17940977
Nat Rev Drug Discov. 2018 Jun;17(6):413-434
pubmed: 29375139
Emerg Infect Dis. 2019 Aug;25(8):1563-1566
pubmed: 31141474
PLoS Negl Trop Dis. 2013 Dec 19;7(12):e2600
pubmed: 24367715
J Virol. 2000 Dec;74(23):10903-10
pubmed: 11069984
Vaccine. 2016 Dec 12;34(51):6597-6609
pubmed: 27395563
J Gen Virol. 2016 Feb;97(2):269-73
pubmed: 26684466
J Infect Dis. 2018 May 18;217(suppl_1):S6-S15
pubmed: 29788345
J Infect Dis. 2015 Oct 1;212 Suppl 2:S443-51
pubmed: 26109675
Vaccine. 2018 Jun 22;36(27):3894-3900
pubmed: 29807712
Lancet Infect Dis. 2018 Jun;18(6):e183-e192
pubmed: 29153266
Proc Natl Acad Sci U S A. 1995 May 9;92(10):4477-81
pubmed: 7753828
Cell. 2001 Sep 7;106(5):539-49
pubmed: 11551502
PLoS Pathog. 2008 Nov;4(11):e1000225
pubmed: 19043556
Emerg Infect Dis. 2010 Jul;16(7):1119-22
pubmed: 20587184
Nature. 2016 May 5;533(7601):100-4
pubmed: 27147028
PLoS One. 2010 May 18;5(5):e10690
pubmed: 20502528
Nat Med. 2005 Jul;11(7):786-90
pubmed: 15937495
N Engl J Med. 2017 Jan 26;376(4):330-341
pubmed: 25830322
J Infect Dis. 2011 Nov;204 Suppl 3:S1090-7
pubmed: 21987746

Auteurs

Anahita Fathi (A)

Department of Medicine, Division of Infectious Diseases, University Medical-Center Hamburg-Eppendorf , Hamburg , Germany.
Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine , Hamburg , Germany.
German Center for Infection Research, Hamburg-Lübeck-Borstel-Riems , Germany.

Christine Dahlke (C)

Department of Medicine, Division of Infectious Diseases, University Medical-Center Hamburg-Eppendorf , Hamburg , Germany.
Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine , Hamburg , Germany.
German Center for Infection Research, Hamburg-Lübeck-Borstel-Riems , Germany.

Marylyn M Addo (MM)

Department of Medicine, Division of Infectious Diseases, University Medical-Center Hamburg-Eppendorf , Hamburg , Germany.
Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine , Hamburg , Germany.
German Center for Infection Research, Hamburg-Lübeck-Borstel-Riems , Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH